S

Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506

Watchlist Manager
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Watchlist
Price: 329.48 CNY 1.74% Market Closed
Market Cap: 136B CNY

Sichuan Biokin Pharmaceutical Co Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sichuan Biokin Pharmaceutical Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Income
ÂĄ3.7B
CAGR 3-Years
N/A
CAGR 5-Years
203%
CAGR 10-Years
N/A
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Operating Income
ÂĄ5.2B
CAGR 3-Years
-10%
CAGR 5-Years
0%
CAGR 10-Years
12%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Income
ÂĄ5.1B
CAGR 3-Years
22%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Income
ÂĄ2.5B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Income
ÂĄ8.1B
CAGR 3-Years
47%
CAGR 5-Years
5%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Income
ÂĄ5B
CAGR 3-Years
13%
CAGR 5-Years
4%
CAGR 10-Years
5%
No Stocks Found

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
136.1B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
29.21 CNY
Overvaluation 91%
Intrinsic Value
Price
S

See Also

What is Sichuan Biokin Pharmaceutical Co Ltd's Operating Income?
Operating Income
3.7B CNY

Based on the financial report for Dec 31, 2024, Sichuan Biokin Pharmaceutical Co Ltd's Operating Income amounts to 3.7B CNY.

What is Sichuan Biokin Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
203%

Back to Top